GlassScriptPhysician profile
Trpko Dimovski
NPI 1205885399
$7,089.29
in general payments reported to CMS, 2019-2025
26 companies · $554 in 2025
The $554 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,173 · 2020: $1,402 · 2021: $118 · 2022: $14.64 · 2023: $587 · 2024: $1,242 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,347.73 | 2019-2025 | |
| Novo Nordisk INC | $441.12 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $319.74 | 2023-2024 | Onyx Frontier, Interstim |
| Amgen INC. | $307.82 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $210.99 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $203.79 | 2019-2025 | Viberzi, Linzess |
| Lilly USA, LLC | $176.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $163.35 | 2023-2024 | Voquezna |
| Medtronic Vascular, INC. | $125.67 | 2019 | |
| Esperion Therapeutics, INC. | $124.74 | 2024 | Nexlizet, Nexletol |
| Exact Sciences Corporation | $117.01 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $76.94 | 2023-2024 | Veozah |
| Merck Sharp & Dohme LLC | $68.63 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.01 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.29 | 2019-2025 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.68 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $45.25 | 2019-2024 | Xarelto |
| Alk-Abello, INC | $34.56 | 2024 | Ragwitek, Odactra, Grastek |
| Sanofi-Aventis U.S. LLC | $29.74 | 2019 | |
| Optinose US, INC. | $29.35 | 2024 | |
| Allergan, INC. | $23.17 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.40 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $15.32 | 2024 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $14.79 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.07 | 2019 | |
| Shire North American Group INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trpko Dimovski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.